Nanobiotix S.A.
Nanobiotix S.A. is a late-stage clinical biotechnology company developing NBTXR3, a first-in-class radioenhancer nanoparticle designed to increase the efficacy of radiotherapy in cancer treatment, with a pipeline targeting multiple solid tumor indications.
- CEO / Founder
- Laurent Levy
- Team Size
- 51-200
- Stage
- Public
- Total Funding
- $113.3M
- Latest Round
- Post-IPO
- Key Investors
- Johnson & Johnson Innovation - JJDC, Inc.; Healthcare Royalty; Janssen
Technology & Products
Key Products
NBTXR3 (radioenhancer nanoparticle); Curadigm Nanoprimer platform
Technological Advantage
Nanobiotix's core advantage lies in its first-in-class radioenhancer, NBTXR3, a hafnium oxide nanoparticle that is injected directly into tumors and amplifies the energy deposited by radiotherapy, leading to increased cancer cell death while sparing surrounding healthy tissue. This mechanism is supported by clinical data showing high objective response rates in various solid tumors, including an 82.5% primary tumor objective response rate in a Phase 1 study. The company has built a substantial intellectual property portfolio, including patents on the nanoparticle composition and its medical applications, which provides a defensible position against competitors. However, the clinical-stage nature of the product and the need for regulatory approvals mean the advantage is contingent on successful trial outcomes and market adoption.
Differentiation
Value Proposition
Enables radiotherapy to be more effective against solid tumors by using hafnium oxide nanoparticles that concentrate energy within cancer cells, potentially improving tumor response rates without increasing systemic toxicity, thereby offering a new treatment option for patients with limited alternatives.
How They Differentiate
Nanobiotix's NBTXR3 is a first-in-class radioenhancer with a unique mechanism of action (intratumoral injection of hafnium oxide nanoparticles) that differentiates it from systemic immunotherapies or other radiotherapy sensitizers. Unlike competitors that focus on systemic drug delivery, NBTXR3 is designed to be locally activated by radiotherapy, potentially offering a higher therapeutic index with fewer systemic side effects.
Market & Competition
Target Customers
Oncology patients with solid tumors undergoing radiotherapy; pharmaceutical partners seeking to enhance radiotherapy-based combination therapies
Industry Verticals
Medical; Oncology
Growth & Milestones
Growth Metrics
Revenue primarily from partnerships and license agreements; clinical-stage with no product sales; 2025 net losses reported in 20-F filing
Major Milestones
2003: Founded; 2020: IPO on NASDAQ; 2021: Reported 82.5% primary tumor objective response rate in Phase 1 study; 2023: Worldwide licensing agreement with Janssen Pharmaceutica NV; 2025: Launched Curadigm Nanoprimer platform; 2026: Joined Euronext Tech Leaders index